InnoCan Pharma Corporation logo

InnoCan Pharma Corporation (IP40)

Market Closed
20 Aug, 20:00
XSTU XSTU
1. 35
+0
+0.3704%
- Market Cap
- P/E Ratio
- Div Yield
0 Volume
0 Eps
1.35
Previous Close
Add Transaction
Day Range
1.31 1.35
Year Range
0.12 9.1
Want to track IP40 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

IP40 closed today higher at €1.35, an increase of 0.3704% from yesterday's close, completing a monthly decrease of -23.4463% or -€0.42. Over the past 12 months, IP40 stock lost -79.3602%.
IP40 is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.

IP40 Chart

InnoCan Pharma Corporation (IP40) FAQ

What is the stock price today?

The current price is €1.35.

On which exchange is it traded?

InnoCan Pharma Corporation is listed on XSTU.

What is its stock symbol?

The ticker symbol is IP40.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has InnoCan Pharma Corporation ever had a stock split?

No, there has never been a stock split.

InnoCan Pharma Corporation Profile

Diversified Consumer Services Industry
Consumer Discretionary Sector
Iris Bincovich CEO
XSTU Exchange
- ISIN
CA Country
11 Employees
- Last Dividend
5 Sep 2025 Last Split
- IPO Date

Overview

InnoCan Pharma Corporation is a pioneering pharmaceutical technology company with a keen focus on developing innovative drug delivery platforms that merge cannabidiol (CBD) with other pharmaceutical ingredients. The company's operations span across the United States, Canada, Europe, and other international markets. It is structured into two main segments: Pharmaceuticals and Consumer Wellness. At its core, InnoCan Pharma is committed to advancing the research and development of CBD loaded exosomes and the LPT CBD-loaded liposome platform. These platforms are designed to ensure precise dosing and the sustained, controlled release of CBD into the bloodstream, targeting conditions such as epilepsy and pain management. Established in 2018 and based in Calgary, Canada, InnoCan Pharma is at the forefront of integrating CBD into pharmaceutical and topical treatment products, aiming to bridge the gap between the health benefits of CBD and the needs of patients worldwide.

Products and Services

  • CBD loaded exosomes - This innovative research and development project focuses on utilizing exosomes (cell-derived nanoparticles) as a delivery system for cannabidiol (CBD). The aim is to target specific diseases with precision, enhancing the therapeutic effects of CBD.
  • LPT CBD-loaded liposome platform - A sophisticated drug delivery platform that encapsulates CBD in liposomes. This technology facilitates accurate dosing and ensures a prolonged and controlled release of CBD into the bloodstream. It is primarily developed for use in managing conditions like epilepsy and chronic pain.
  • Branded CBD integrated pharmaceutical and topical treatment products - InnoCan Pharma is actively involved in the commercialization and sale of branded pharmaceutical and topical treatments that integrate CBD. These products are designed to meet the needs of patients seeking reliable, CBD-based therapies.
  • Self-care products for a healthier lifestyle - Beyond its pharmaceutical technology focus, InnoCan also develops and markets a range of self-care products. These offerings aim to promote a healthier lifestyle through the benefits of CBD and other wellness-focused ingredients.
  • Product Brand Names - The company markets its diverse product portfolio under several brand names, including Innocan Pharma, R&G Relief & Go, Shir, Synony, and Add On. Each brand caters to different aspects of health and wellness, leveraging the therapeutic potential of CBD.

Contact Information

Address: 1015, 926 – 5 Avenue SW
Phone: 403 777 1519